Annexon (NASDAQ:ANNX) CFO Jennifer Lew Sells 7,851 Shares of Stock

Annexon, Inc. (NASDAQ:ANNX) CFO Jennifer Lew sold 7,851 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $5.11, for a total value of $40,118.61. Following the sale, the chief financial officer owned 113,765 shares of the company’s stock, valued at $581,339.15. This trade represents a 6.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Annexon Stock Down 3.9%

Shares of Annexon stock traded down $0.20 on Friday, reaching $4.90. The stock had a trading volume of 1,749,100 shares, compared to its average volume of 1,986,881. The stock has a market capitalization of $586.19 million, a P/E ratio of -3.48 and a beta of 1.17. Annexon, Inc. has a 1 year low of $1.28 and a 1 year high of $7.18. The company has a 50 day moving average price of $5.58 and a 200 day moving average price of $3.94.

Annexon News Roundup

Here are the key news stories impacting Annexon this week:

• Neutral Sentiment: Short-interest reports for Feb. 19–20 show 0 shares of reported short interest and a 0.0 days-to-cover metric — this appears to be a data/reporting anomaly (NaN changes). The readings do not indicate meaningful new short activity to explain the move. Short Interest Report
• Negative Sentiment: EVP Michael Overdorf sold 6,225 shares at an average $5.10 (≈$31.7k); his holdings fell ~4.8%. Form 4 – Overdorf
• Negative Sentiment: EVP Ted Yednock sold 7,857 shares at an average $5.11 (≈$40.1k); his position dropped ~7.5%. Form 4 – Yednock
• Negative Sentiment: EVP Dean Richard Artis sold 5,290 shares at an average $5.10 (≈$27.0k); his holding decreased ~4.1%. Form 4 – Artis
• Negative Sentiment: CFO Jennifer Lew sold 7,851 shares at an average $5.11 (≈$40.1k); her stake fell ~6.5%. Form 4 – Lew
• Negative Sentiment: Insider Jamie Dananberg sold 5,290 shares at an average $5.10 (≈$27.0k); his holding declined ~6.7%. Form 4 – Dananberg

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on ANNX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a research note on Wednesday, January 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Wednesday, January 14th. Chardan Capital began coverage on shares of Annexon in a report on Tuesday, December 23rd. They set a “buy” rating and a $16.00 price target on the stock. Finally, Wells Fargo & Company raised their target price on Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ANNX. Wealth Enhancement Advisory Services LLC raised its stake in shares of Annexon by 13.6% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock valued at $100,000 after acquiring an additional 2,348 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Annexon by 65.6% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after purchasing an additional 2,785 shares during the period. Susquehanna Portfolio Strategies LLC grew its stake in shares of Annexon by 0.8% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after acquiring an additional 2,875 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Annexon by 21.7% in the fourth quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock valued at $124,000 after acquiring an additional 4,410 shares in the last quarter. Finally, Citizens Financial Group Inc. RI increased its holdings in Annexon by 14.3% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 40,000 shares of the company’s stock worth $122,000 after purchasing an additional 5,000 shares during the period.

Annexon Company Profile

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.